Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Perspectives on clinical trials in spinal muscular atrophy.

Journal of child neurology - 1 Aug 2007

Swoboda Kathryn J, Kissel John T, Crawford Thomas O, Bromberg Mark B, Acsadi Gyula, D'Anjou Guy, Krosschell Kristin J, Reyna Sandra P, Schroth Mary K, Scott Charles B, Simard Louise R

Abstract excerpt

Spinal muscular atrophy is one of the most heterogeneous of the single-gene neuromuscular disorders. The broad spectrum of severity, with onset from the prenatal period to adulthood, presents unique challenges in the design and implementation of clinical trials. The clinical classification of sub...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Cyclic AMP Response Element-Binding Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Muscle, Skeletal

Share to Nerve Growth Factors

Share to RNA-Binding Proteins

Share to SMN Complex Proteins

Share to Spinal Muscular Atrophies of Childhood

Source

Open in PubMed Open full text

Identifiers

PMID: 17761650
DOI: 10.1177/0883073807305665
PMCID: PMC3260051

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-17761650-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Perspectives on clinical trials in spinal muscular atrophy.PMID 17761650Read ↗

Spinal muscular atrophy: from rags to riches.Semantic proximity Read ↗

Pharmacotherapy for Spinal Muscular Atrophy in Babies and Children: A Review of Approved and Experimental TherapiesSemantic proximity Read ↗

Spinal muscular atrophy: A changing phenotype beyond the clinical trials.Semantic proximity Read ↗

First drug to treat spinal muscular atrophy gets FDA approval: Costly injectable shown to stall debilitating muscle-wasting effects of rare genetic disorder.Semantic proximity Read ↗

Decision-making and challenges within the evolving treatment algorithm in spinal muscular atrophy: a clinical perspective.Semantic proximity Read ↗

Muscular dystrophy: new challenges and review of the current clinical trials.Semantic proximity Read ↗

Genetic approaches to the treatment of inherited neuromuscular diseasesSemantic proximity Read ↗

Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA)Semantic proximity Read ↗

Current understanding of and emerging treatment options for spinal muscular atrophy with respiratory distress type 1 (SMARD1)Semantic proximity Read ↗

Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy TherapySemantic proximity Read ↗

[Gene-based treatment in spinal muscular atrophy].Semantic proximity Read ↗

Gene therapy for neuromuscular disorders: prospects and ethicsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.